earnings

It seems the Alzheimers data has dominated the earnings ! And SPINRAZA as expected contributing much to revenues. https://news.alphastreet.com/biogen-stock-gains-on-upbeat-q2-results/

Very positive results indeed ! All segments reporting double digit growth. https://news.alphastreet.com/abbott-posts-17-sales-growth-for-q2-beats-estimates/

Healthcare giant Johnson & Johnson (JNJ) reported a beat on both the top and bottom line expectations as it posted its Q2 2018 earnings. This was aided by a double-digit growth in Pharmaceutical business and the accelerating sales momentum in the Medical Devices business...

Medtronic posted better-than-expected fourth quarter earnings. Earnings came in at $1.07 a share. Excluding items, the company earned $1.42, topping analysts’ estimate of $1.39. Revenue came in at $8.1 billion, meeting the consensus estimate of $8 billion. Strong global demand for the new...

Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters. The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in...

Valeant reported revenue of $1.99 billion for the first quarter of 2018, down 5% YoY Organic revenue growth was 2%, driven by growth in the Salix business and the Bausch + Lomb/International segment. Net loss of $2.69 billion, primarily due to a decrease in the benefit from income taxes and...

CVS Health reported an increase of 2.6% in revenues to around $45.7 billion for the first quarter of 2018 compared to the prior year period. Net income rose 4.7% to $998 million or $0.98 per share. Adjusted EPS came in at $1.48, beating market estimates. The quarterly results benefited from...

Gilead Sciences (GILD) reported a 43% dip in earnings for the first quarter due to lower product sales and prescription trends. Higher competition and lower sales of certain hepatitis C products too impacted sales during the quarter. Infographics of the results. The market has huge hopes for...

Merck reported a 6% increase in worldwide sales to $10 billion for the first quarter of 2018 compared to the prior year period. Pharmaceutical sales grew 9% to $8.9 billion driven primarily by growth in oncology, hospital acute care and diabetes. This was partially offset by lower sales in...

Pfizer posted a 1% improvement in revenues of $12.9 billion for the first quarter of 2018. Reported net income jumped 14% to $3.5 billion, while adjusted net income grew 11% to $4.6 billion. Reported EPS rose 15% to $0.59, while adjusted EPS grew 12% to $0.77 compared to last year. While revenue...

Allergan plc reported a 3% improvement in revenues to $3.7 billion for the first quarter of 2018 compared to the prior year period, driven by a 13% increase in its core business which includes the Botox and Juvederm brands. Net loss for the quarter was $332.5 million or $0.99 per diluted share...

Alexion reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study. The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue...

AbbVie’s first quarter results topped analyst consensus both on earnings and sales front, driven by double-digit sales growth from Humira, Imbruvica, and HCV. Sales improved 21.4% to $7.9 billion, while adjusted earnings came in at $1.87, up 46%. The company also has decided to buyback shares to...

Amgen reported an increase in first quarter earnings, driven by broad-based growth in product sales. Both earnings and sales topped street estimates. Earnings rose 16% year-over-year to $3.25 per share during the quarter. Besides higher product sales, the growth was also driven by a decline in...

Biogen, whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings. Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of...

Abbott reported worldwide sales of $7.4 billion for the first quarter of 2018, an increase of 16.7% versus the prior-year period, helped by new product launches. Net earnings on a GAAP basis came in at $418 million or $0.23 per share, down slightly from the prior-year quarter. On an adjusted...

Intuitive Surgical reported a first-quarter profit that exceeded market consensus. The company’s flagship da Vinci surgical system continues to be a revenue driver for the instruments and accessories segment. With total revenue jumping 25% to about $858 million, the instruments maker saw its...

JNJ reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%. Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain...

Sale of its blockbuster arthritis drug, Remicade, was particularly impacted by the rising influence of biosimilars, especially in the international markets. It needs to be seen how much the company has resisted this trend in the first quarter...

https://news.alphastreet.com/benefiting-from-tax-gains-valeant-pharma-swings-to-profit-in-q4/ The company now forecasts full year revenues below its previous expectation